Back to Journals » Drug Design, Development and Therapy » Volume 9

A meta-analysis for CXCR4 as a prognostic marker and potential drug target in non-small cell lung cancer

Authors Zhang C, Li J, Han Y, Jiang J

Received 25 January 2015

Accepted for publication 14 April 2015

Published 24 June 2015 Volume 2015:9 Pages 3267—3278

DOI https://doi.org/10.2147/DDDT.S81564

Checked for plagiarism Yes

Review by Single anonymous peer review

Peer reviewer comments 3

Editor who approved publication: Professor Shu-Feng Zhou


Changyuan Zhang,1,* Jie Li,2,* Yi Han,3 Jian Jiang4

1Department of Cardiothoracic Surgery, Inner Mongolia Autonomous Region People’s Hospital, Inner Mongolia; 2Department of Oncology, 3Department of Thoracic Surgery, Beijing Chest Hospital, 4Department of Thoracic Surgery, Beijing Tongren Hospital, Capital Medical University, Beijing, People’s Republic of China

*These authors contributed equally to this work


Background: Recent reports have shown that C-X-C chemokine receptor type 4 (CXCR4) is a candidate oncogene in several types of human tumors, including non-small cell lung cancer (NSCLC). However, the correlation between CXCR4 expression and clinicopathological characteristics of NSCLC remains controversial and has not been emphasized. The aim of this study is to quantitatively evaluate the association of CXCR4 expression with the incidence of NSCLC and clinicopathological characteristics by performing a meta-analysis.
Methods: A detailed literature search was carried out for related research publications. Only articles in which CXCR4 expression was detected by immunohistochemical staining were included. Odds ratio (OR) and hazard ratio (HR) with 95% confidence intervals (CIs) were calculated and summarized.
Results: Final analysis of 1,872 NSCLC patients from 19 eligible studies was performed. We observed that CXCR4 expression was significantly higher in NSCLC than in normal lung tissue, based on the pooled OR from ten studies, including 678 NSCLCs and 189 normal lung tissues (OR =16.66, 95% CI =6.94–40.02, P<0.00001). CXCR4 expression was also significantly associated with clinical stages, metastatic status, and overall survival (OS) in NSCLC patients. In addition, CXCR4 mRNA high expression was found to correlate with worse OS of all NSCLC patients followed for 20 years, HR =1.24, P=0.0047.
Conclusion: The present meta-analysis indicated that CXCR4 protein expression is associated with an increased risk and worse survival in NSCLC patients. The aberrant CXCR4 protein and mRNA expression play an important role in the carcinogenesis and metastasis of NSCLC.

Keywords: prognosis, meta-analysis, odds ratio, hazard ratio

Creative Commons License This work is published and licensed by Dove Medical Press Limited. The full terms of this license are available at https://www.dovepress.com/terms.php and incorporate the Creative Commons Attribution - Non Commercial (unported, v3.0) License. By accessing the work you hereby accept the Terms. Non-commercial uses of the work are permitted without any further permission from Dove Medical Press Limited, provided the work is properly attributed. For permission for commercial use of this work, please see paragraphs 4.2 and 5 of our Terms.

Download Article [PDF]  View Full Text [HTML][Machine readable]